Related Experiment Video
Updated: Jun 23, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Aspirin plus clopidogrel and risk of infection after coronary artery bypass surgery
Elena Blasco-Colmenares1, Trish M Perl, Eliseo Guallar
1Department of Anesthesiology, Johns Hopkins Hospital, 298 Meyer Bldg, 600 N Wolfe St, Baltimore, MD 21287, USA.
Insights
Preoperative dual antiplatelet therapy with aspirin and clopidogrel increases infection risk after coronary artery bypass surgery. This highlights the need for further research into managing antiplatelet medications before surgical procedures.
Area of Science:
- Cardiology
- Infectious Disease
- Surgical Outcomes
Background:
- The risks of combining aspirin and clopidogrel before surgery are not fully understood.
- Platelet suppression may elevate postoperative infection risk by impairing hemostasis or immunity.
Purpose of the Study:
- To investigate the association between preoperative dual antiplatelet therapy (aspirin plus clopidogrel) versus aspirin monotherapy and the incidence of postoperative infection.
- To analyze the risk of surgical site infection and bacteremia within 30 days following coronary artery bypass surgery.
Main Methods:
- Retrospective cohort study involving 1677 patients undergoing coronary artery bypass surgery.
- Comparison of 30-day infection rates between patients receiving dual antiplatelet therapy and those on aspirin monotherapy.
- Statistical analysis included hazard ratios, confidence intervals, and propensity score adjustments.
Main Results:
- The 30-day infection incidence was higher with dual antiplatelet therapy (23.1%) compared to aspirin monotherapy (16.1%).
- Dual antiplatelet therapy remained associated with increased infection risk after adjusting for various risk factors (adjusted HR, 1.42).
- Higher transfusion rates were observed in the dual antiplatelet therapy group, but transfusion played a minor role in mediating infection risk.
Conclusions:
- Preoperative aspirin plus clopidogrel use is linked to a higher risk of infection after coronary artery bypass surgery.
- Further research is needed to clarify the risks and benefits of uninterrupted dual antiplatelet therapy in surgical patients.
- The impact of platelet inhibition on infectious outcomes, especially in high-risk populations, requires further investigation.
Background:
The risks associated with the use of the combination of aspirin and clopidogrel before surgery are incompletely understood. Pharmacologic suppression of platelet function may increase the risk of postoperative infection by inhibiting hemostasis, immunity, or both.
Methods:
We performed a retrospective cohort study of 1677 patients undergoing coronary artery bypass surgery to determine the relationship of the preoperative use of aspirin plus clopidogrel vs aspirin alone to the 30-day incidence of postoperative surgical site infection and bacteremia.
Results:
The cumulative incidence of infection at 30 days was 23.1% and 16.1% in patients who were receiving dual antiplatelet therapy and aspirin monotherapy, respectively (unadjusted hazard ratio [HR], 1.51; 95% confidence interval [CI], 1.09-2.08). The risk of infection remained higher among patients who were receiving dual antiplatelet therapy after adjustment for demographic, socioeconomic, preoperative, and intraoperative risk factors (HR, 1.42; 95% CI, 1.01-2.00) and propensity score (HR, 1.43; 95% CI, 1.01-2.01]). Transfusion rates were also higher among patients who were receiving dual antiplatelet therapy than among patients who were receiving aspirin monotherapy (68.4% vs 60.4%, P = .04), but transfusion played a modest role in mediating the risk of infection (adjusted HR, 1.37; 95% CI, 0.96-1.93]). Mortality rates at 30 days were 5.2% and 3.1% in patients who were receiving dual antiplatelet and aspirin monotherapy, respectively (adjusted HR, 1.44; 95% CI, 0.70-2.99]).
Conclusions:
Preoperative use of aspirin plus clopidogrel is associated with an increased risk of infection after coronary artery bypass surgery. These findings merit additional work to clarify the risks and benefits of uninterrupted dual antiplatelet therapy in surgical patients and the impact of platelet inhibition on infectious outcomes in populations that are at heightened infectious risk.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
Peripheral Artery Disease III: Interprofessional Care